Frank McCormick, PhD, FRS, DSc (Hon)

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Frank McCormick, PhD, FRS, DSc (Hon)

Professor Emeritus, UCSF Helen Diller Family Comprehensive Cancer Center
David A. Wood Distinguished Professorship of Tumor Biology and Cancer Research

mccormic@cc.ucsf.edu

Phone: (415) 502-1710 (voice)
Box 0128, UCSF
San Francisco, CA 94143-0128

View on UCSF Profiles


Additional Websites


Education

University of Birmingham, England, B.Sc., 1972, Biochemistry
University of Cambridge, England, Ph.D., 1975, Biochemistry


Professional Experience

  • 1975-1978
    Professor Seymour S. Cohen, SUNY at Stony Brook (Post Doctoral Fellow)
  • 1978-1981
    Dr. Alan Smith, Imperial Cancer Research Fund, London (Post Doctoral Fellow)
  • 1981-1990
    Cetus Corporation (Director of Molecular Biology)
  • 1990-1991
    Cetus Corporation (Vice President, Research)
  • 1991-1992
    Chiron Corporation (Vice President, Research)
  • 1992-1996
    Onyx Pharmaceuticals (Founder, Chief Scientific Officer)
  • 1997-2013
    University of California, San Francisco, Microbiology & Immunology (Professor)
  • 1997-2014
    University of California, San Francisco, Cancer Center (Director, Associate Dean)
  • 2013-present
    University of California, San Francisco, Microbiology & Immunology (Professor Emeritus)
  • 2013-present
    University of California, San Francisco, Cancer Center (Professor Emeritus)
  • 2013-present
    National Cancer Institute, Frederick National Laboratory for Cancer Research, Project Leader

Honors & Awards

  • 1996
    Fellow of the Royal Society
  • 2002
    Bristol Myers Squibb Unrestricted Cancer Research Grant
  • 2002
    AACR – G.H.A. Clowes Memorial Award
  • 2002
    Novartis Drew Award in Biomedical Research
  • 2003
    University of Chicago, Cancer Research Center, Shubitz Award
  • 2005
    Institute of Medicine
  • 2010
    ASCO Science of Oncology Award
  • 2014
    National Academy of Science

Selected Publications

  1. McCormick F. The potential of targeting Ras proteins in lung cancer. Expert Opin Ther Targets. 2015 Apr; 19(4):451-4.
    View on PubMed
  2. Martins MM, Zhou AY, Corella A, Horiuchi D, Yau C, Rakshandehroo T, Gordan JD, Levin RS, Johnson J, Jascur J, Shales M, Sorrentino A, Cheah J, Clemons PA, Shamji AF, Schreiber SL, Krogan NJ, Shokat KM, McCormick F, Goga A, Bandyopadhyay S. Linking Tumor Mutations to Drug Responses via a Quantitative Chemical-Genetic Interaction Map. Cancer Discov. 2015 Feb; 5(2):154-67.
    View on PubMed
  3. Phuchareon J, Overdevest JB, McCormick F, Eisele DW, van Zante A, Tetsu O. Fatty Acid binding protein 7 is a molecular marker in adenoid cystic carcinoma of the salivary glands: implications for clinical significance. Transl Oncol. 2014 Dec; 7(6):780-7.
    View on PubMed
  4. Guinney J, Dienstmann R, Ferté C, Friend S, McCormick F. Social interactomes for enabling research communities. Cancer Discov. 2014 Nov; 4(11):1265-8.
    View on PubMed
  5. Phuchareon J, van Zante A, Overdevest JB, McCormick F, Eisele DW, Tetsu O. c-Kit Expression is Rate-Limiting for Stem Cell Factor-Mediated Disease Progression in Adenoid Cystic Carcinoma of the Salivary Glands. Transl Oncol. 2014 Oct; 7(5):537-45.
    View on PubMed
  6. Sos ML, Levin RS, Gordan JD, Oses-Prieto JA, Webber JT, Salt M, Hann B, Burlingame AL, McCormick F, Bandyopadhyay S, Shokat KM. Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors. Cell Rep. 2014 Aug 21; 8(4):1037-48.
    View on PubMed
  7. Yuan TL, Fellmann C, Lee CS, Ritchie CD, Thapar V, Lee LC, Hsu DJ, Grace D, Carver JO, Zuber J, Luo J, McCormick F, Lowe SW. Development of siRNA payloads to target KRAS-mutant cancer. Cancer Discov. 2014 Oct; 4(10):1182-97.
    View on PubMed
  8. Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer. 2014 Jul; 14(7):455-67.
    View on PubMed
  9. Nwachukwu BU, McCormick FM, Schairer WW, Frank RM, Provencher MT, Roche MW. Unicompartmental knee arthroplasty versus high tibial osteotomy: United States practice patterns for the surgical treatment of unicompartmental arthritis. J Arthroplasty. 2014 Aug; 29(8):1586-9.
    View on PubMed
  10. Thai M, Graham NA, Braas D, Nehil M, Komisopoulou E, Kurdistani SK, McCormick F, Graeber TG, Christofk HR. Adenovirus E4ORF1-induced MYC activation promotes host cell anabolic glucose metabolism and virus replication. Cell Metab. 2014 Apr 1; 19(4):694-701.
    View on PubMed
  11. Stephen AG, Esposito D, Bagni RK, McCormick F. Dragging ras back in the ring. Cancer Cell. 2014 Mar 17; 25(3):272-81.
    View on PubMed
  12. Holderfield M, Lorenzana E, Weisburd B, Lomovasky L, Boussemart L, Lacroix L, Tomasic G, Favre M, Vagner S, Robert C, Ghoddusi M, Daniel D, Pryer N, McCormick F, Stuart D. Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors. Cancer Res. 2014 Apr 15; 74(8):2238-45.
    View on PubMed
  13. Kashiyama T, Oda K, Ikeda Y, Shiose Y, Hirota Y, Inaba K, Makii C, Kurikawa R, Miyasaka A, Koso T, Fukuda T, Tanikawa M, Shoji K, Sone K, Arimoto T, Wada-Hiraike O, Kawana K, Nakagawa S, Matsuda K, McCormick F, Aburatani H, Yano T, Osuga Y, Fujii T. Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423. PLoS One. 2014; 9(2):e87220.
    View on PubMed
  14. Widemann BC, Acosta MT, Ammoun S, Belzberg AJ, Bernards A, Blakeley J, Bretscher A, Cichowski K, Clapp DW, Dombi E, Evans GD, Ferner R, Fernandez-Valle C, Fisher MJ, Giovannini M, Gutmann DH, Hanemann CO, Hennigan R, Huson S, Ingram D, Kissil J, Korf BR, Legius E, Packer RJ, McClatchey AI, McCormick F, North K, Pehrsson M, Plotkin SR, Ramesh V, Ratner N, Schirmer S, Sherman L, Schorry E, Stevenson D, Stewart DR, Ullrich N, Bakker AC, Morrison H. CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies. Am J Med Genet A. 2014 Mar; 164A(3):563-78.
    View on PubMed
  15. Salt MB, Bandyopadhyay S, McCormick F. Epithelial-to-mesenchymal transition rewires the molecular path to PI3K-dependent proliferation. Cancer Discov. 2014 Feb; 4(2):186-99.
    View on PubMed
  16. Yuan TL, McCormick F. Killing tumors by keeping ras and PI3' kinase apart. Cancer Cell. 2013 Nov 11; 24(5):562-3.
    View on PubMed
  17. Nan X, Collisson EA, Lewis S, Huang J, Tamgüney TM, Liphardt JT, McCormick F, Gray JW, Chu S. Single-molecule superresolution imaging allows quantitative analysis of RAF multimer formation and signaling. Proc Natl Acad Sci U S A. 2013 Nov 12; 110(46):18519-24.
    View on PubMed
  18. Timmerman LA, Holton T, Yuneva M, Louie RJ, Padró M, Daemen A, Hu M, Chan DA, Ethier SP, van 't Veer LJ, Polyak K, McCormick F, Gray JW. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell. 2013 Oct 14; 24(4):450-65.
    View on PubMed
  19. Lyons J, Bastian BC, McCormick F. MC1R and cAMP signaling inhibit cdc25B activity and delay cell cycle progression in melanoma cells. Proc Natl Acad Sci U S A. 2013 Aug 20; 110(34):13845-50.
    View on PubMed
  20. Holderfield M, Merritt H, Chan J, Wallroth M, Tandeske L, Zhai H, Tellew J, Hardy S, Hekmat-Nejad M, Stuart DD, McCormick F, Nagel TE. RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation. Cancer Cell. 2013 May 13; 23(5):594-602.
    View on PubMed

Go to UCSF Profiles, powered by CTSI